Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Lilly has satisfied wholesalers’ backorders for Mounjaro and is continuingly shipping all six doses of the diabetes med, a company spokesperson said. Still, it’s too early to say the shortage ...

Eli Lily's Mounjaro is more effective for weight loss than Ozempic, study shows Patients on Mounjaro were more likely to lose 5%, 10% and 15% of their body weight ...

A dose of Eli Lilly's diabetes drug Mounjaro has limited availability through February 2024, according to the U.S. Food and Drug Administration's website, due to an increase in demand.